AC Immune (ACIU) vs Lyell Immunopharma, Inc. (LYEL)
AC Immune and Lyell Immunopharma, Inc. are both Biotechnology companies. AC Immune and Lyell Immunopharma, Inc. are of similar size ($249.4M and $248.0M). Lyell Immunopharma, Inc. grew revenue faster over the last twelve months: −55.0% against −85.6%. AC Immune has the higher net margin (−1,783.7% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 16 metrics below, AC Immune leads on 11 and Lyell Immunopharma, Inc. on 5.
Valuation
Profitability
| Metric | ACIU | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (1,745.75%) | (949,981.48%) | 0.00% |
| Net margin | (1,783.66%) | (920,285.19%) | 0.00% |
| Free cash flow margin | 0.00% | (647,681.48%) | 0.00% |
| Return on equity | 0.00% | (93.28%) | (57.72%) |
| Return on assets | 0.00% | (71.34%) | (49.22%) |
| Return on invested capital | 0.00% | (539.53%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack